Jacobs Levy Equity Management Inc. Purchases 288,678 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Jacobs Levy Equity Management Inc. increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,848,071 shares of the company's stock after purchasing an additional 288,678 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 2.18% of Verve Therapeutics worth $10,423,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after buying an additional 3,964 shares during the period. IFP Advisors Inc increased its stake in Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Verve Therapeutics during the fourth quarter worth $50,000. Impact Partnership Wealth LLC bought a new stake in Verve Therapeutics during the fourth quarter worth $70,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after purchasing an additional 1,676 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Price Performance

NASDAQ VERV traded up $0.31 during trading hours on Friday, reaching $4.63. The company's stock had a trading volume of 2,963,940 shares, compared to its average volume of 1,853,035. The firm has a fifty day simple moving average of $4.82 and a 200-day simple moving average of $5.87. Verve Therapeutics, Inc. has a 52 week low of $2.86 and a 52 week high of $9.31. The stock has a market cap of $412.73 million, a P/E ratio of -1.88 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. On average, research analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analyst Weigh In

VERV has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Finally, Guggenheim raised their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.